Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
RARα Antibody 2554 40 µl
Western Blotting
M R 55 Rabbit 
RARγ1 (D3A4) XP® Rabbit mAb 8965 40 µl
Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence
H M 58 Rabbit IgG
RXRα (D6H10) Rabbit mAb 3085 40 µl
Western Blotting Immunoprecipitation
H M R 53 Rabbit IgG
Glucocorticoid Receptor (D8H2) XP® Rabbit mAb 3660 40 µl
Western Blotting Immunoprecipitation Immunofluorescence Flow Cytometry Chromatin Immunoprecipitation
H M R Mk 80, 91, 94 Rabbit IgG
Progesterone Receptor A/B (D8Q2J) XP® Rabbit mAb 8757 40 µl
Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence Flow Cytometry Chromatin Immunoprecipitation
H 90 (PR-A), 118 (PR-B) Rabbit IgG
Androgen Receptor (D6F11) XP® Rabbit mAb 5153 40 µl
Western Blotting Immunohistochemistry Immunofluorescence Flow Cytometry
H 110 Rabbit IgG
Estrogen Receptor α (D8H8) Rabbit mAb 8644 40 µl
Western Blotting Immunoprecipitation Immunofluorescence Chromatin Immunoprecipitation
H 66 Rabbit IgG
PPARγ (C26H12) Rabbit mAb 2435 40 µl
Western Blotting Immunohistochemistry Immunofluorescence
H M 53, 57 Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody 7074 100 µl
Western Blotting
Goat 

Product Description

The Nuclear Receptor Antibody Sampler Kit provides an economical means to evaluate the presence and status of nuclear receptors. This kit contains enough primary antibody to perform four western blots per primary.


Specificity / Sensitivity

Each antibody in the Nuclear Receptor Antibody Sampler Kit recognizes endogenous levels of total respective protein. Glucocorticoid Receptor (D8H2) XP® Rabbit mAb is predicted to cross-react with all known alternative translation start site generated isoforms of glucocorticoid receptor-α and glucocorticoid receptor-β, and does not cross-react with mineralocorticoid receptor. Progesterone Receptor A/B (D8Q2J) XP® Rabbit mAb does not cross-react with either the glucocorticoid receptor or the mineralocorticoid receptor. RARγ1 (D3A4) XP® Rabbit mAb is not predicted to cross-react with RARγ2, and does not cross-react with either RARα or RARβ. RXRα (D6H10) Rabbit mAb does not cross-react with either RXRβ or RXRγ.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the sequence of human RARα protein. Polyclonal antibodies are purified by protein A and peptide affinity chromatography.

Monoclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminal region of human androgen receptor protein, residues in the carboxy terminus of human ERα protein, residues surrounding Leu378 of human glucocorticoid receptor protein, residues surrounding Asp69 of human PPARγ protein, residues surrounding Tyr541 of human progesterone receptor protein, residues near the amino terminus of human RARγ1 protein, or residues near the amino terminus of human RXRα protein.

Nuclear Receptors are transcription factors responsible for sensing bioactive molecules, including steroid and thyroid hormones. They are regulated by multiple posttranslational modifications, which in turn impacts their ability to regulate the expression of specific genes involved in the control of reproduction, development, and metabolism.

Androgen receptor (AR), a zinc finger transcription factor belonging to the nuclear receptor superfamily, is activated by phosphorylation and dimerization upon ligand binding (1). This promotes nuclear localization and binding of AR to androgen response elements in androgen target genes. AR plays a crucial role in several stages of male development and the progression of prostate cancer (2,3).

Estrogen receptor α (ERα), a member of the steroid receptor superfamily, contains highly conserved DNA binding and ligand binding domains (4). Through its estrogen-independent and estrogen-dependent activation domains (AF-1 and AF-2, respectively), ERα regulates transcription by recruiting coactivator proteins and interacting with general transcriptional machinery (5).

Glucocorticoid hormones control cellular proliferation, inflammation, and metabolism through their association with the glucocorticoid receptor (GR)/NR3C1, a member of the nuclear hormone receptor superfamily of transcription factors (6).

Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the ligand-activated nuclear receptor superfamily and functions as a transcriptional activator (7). PPARγ is preferentially expressed in adipocytes, as well as in vascular smooth muscle cells and macrophages (8). Besides its role in mediating adipogenesis and lipid metabolism (8), PPARγ also modulates insulin sensitivity, cell proliferation, and inflammation (9).

Human progesterone receptor (PR) is expressed as two forms: the full length PR B and the short form PR A. PR A lacks the first 164 amino acid residues of PR B (10,11). Both PR A and PR B are ligand activated, but differ in their relative ability to activate target gene transcription (12,13).

Nuclear retinoic acid receptors (RARs) consist of three subtypes encoded by separate genes: α (NR1B1), β (NR1B2), and γ (NR1B3). For each subtype, there are at least two isoforms, which are generated by differential promoter usage and alternative splicing and differ only in their N-terminal regions. Retinoids, which are metabolites of vitamin A, serve as ligands for RARs (14). RARs function as ligand-dependent transcriptional regulators and are found to be heterodimerized with retinoid X receptors (RXRs). These transcriptionally active dimers regulate the expression of genes involved in cellular differentiation, proliferation, and apoptosis (15,16).

The human retinoid X receptors are encoded by three distinct genes (RXRα, RXRβ, and RXRγ) and bind selectively and with high affinity to the vitamin A derivative, 9-cis-retinoic acid. RXRs are type-II nuclear hormone receptors that are largely localized to the nuclear compartment independent of ligand binding. Nuclear RXRs form heterodimers with nuclear hormone receptor subfamily 1 proteins, including thyroid hormone receptor, retinoic acid receptors, vitamin D receptor, peroxisome proliferator-activated receptors, liver X receptors, and farnesoid X receptor (17).


1.  Li, J. and Al-Azzawi, F. (2009) Maturitas 63, 142-8.

2.  Evans, R.M. (1988) Science 240, 889-95.

3.  Avila, D.M. et al. (2001) J. Steroid. Biochem. Mol. Biol. 76, 135-142.

4.  Kastner, P. et al. (1990) EMBO J 9, 1603-14.

5.  Montgomery, J.S. et al. (2001) J. Pathol. 195, 138-146.

6.  Giangrande, P.H. et al. (2000) Mol Cell Biol 20, 3102-15.

7.  Mangelsdorf, D.J. et al. (1995) Cell 83, 835-9.

8.  Wen, D.X. et al. (1994) Mol Cell Biol 14, 8356-64.

9.  Glass, C.K. and Rosenfeld, M.G. (2000) Genes Dev 14, 121-41.

10.  Yamamoto, K.R. (1985) Annu. Rev. Genet 19, 209-252.

11.  Tontonoz, P. et al. (1995) Curr. Opin. Genet. Dev. 5, 571-576.

12.  Rosen, E.D. et al. (1999) Mol. Cell 4, 611-617.

13.  Murphy, G.J. and Holder, J.C. (2000) Trends Pharmacol. Sci. 21, 469-474.

14.  Rochette-Egly, C. and Germain, P. (2009) Nucl Recept Signal 7, e005.

15.  Delacroix, L. et al. (2010) Mol Cell Biol 30, 231-44.

16.  Eifert, C. et al. (2006) Mol Reprod Dev 73, 796-824.

17.  Gronemeyer, H. et al. (2004) Nat Rev Drug Discov 3, 950-64.


Entrez-Gene Id 367 , 2099 , 2908 , 5468 , 5241 , 5914 , 5916 , 6256
Swiss-Prot Acc. P10275 , P03372 , P04150 , P37231 , P06401 , P10276 , P13631 , P19793

Protein Specific References

Wen Y et al. (2000) Cancer Res 60, 6841–5

Fu M et al. (2000) J Biol Chem 275, 20853–60

Lin HK et al. (2001) Proc Natl Acad Sci U S A 98, 7200–5

Lin HK et al. (2003) J Biol Chem 278, 50902–7

Gioeli D et al. (2006) Mol Endocrinol 20, 503–15

Montie HL et al. (2011) J Neurosci 31, 17425–36

Linn DE et al. (2012) J Biol Chem 287, 22959–68

Willder JM et al. (2013) Br J Cancer 108, 139–48

Chen D et al. (2000) Mol Cell 6, 127–37

Métivier R et al. (2002) EMBO J 21, 3443–53

Dutertre M and Smith CL (2003) Mol Endocrinol 17, 1296–314

Lu Q et al. (2003) J Biol Chem 278, 4639–45

Murphy L et al. (2004) Clin Cancer Res 10, 1354–9

Murphy LC et al. (2004) Clin Cancer Res 10, 5902–6

Cui Y et al. (2004) Cancer Res 64, 9199–208

Staka CM et al. (2005) Endocr Relat Cancer 12 Suppl 1, S85–97

Chen J et al. (2005) Blood 106, 328–37

Medunjanin S et al. (2005) J Biol Chem 280, 33006–14

Yamashita H et al. (2005) Breast Cancer Res 7, R753–64

Gburcik V et al. (2005) Mol Cell Biol 25, 3421–30

Shah YM and Rowan BG (2005) Mol Endocrinol 19, 732–48

Kim MY et al. (2006) Mol Endocrinol 20, 1479–93

Kuske B et al. (2006) Endocr Relat Cancer 13, 1121–33

Sekine Y et al. (2007) Oncogene 26, 6038–49

Britton DJ et al. (2008) J Am Soc Mass Spectrom 19, 729–40

Thomas RS et al. (2008) J Mol Endocrinol 40, 173–84

Kok M et al. (2009) J Natl Cancer Inst 101, 1725–9

Ma Y et al. (2010) Mol Endocrinol 24, 76–90

He X et al. (2010) Oncogene 29, 2238–51

Cañas A et al. (2012) Breast Cancer Res 14, R153

Bhatt S et al. (2012) Mol Cell Biol 32, 1928–43

Itoh M et al. (2002) Mol Endocrinol 16, 2382–92

Wang Z et al. (2007) Mol Endocrinol 21, 625–34

Kotitschke A et al. (2009) Mol Endocrinol 23, 1726–45

Avenant C et al. (2010) Biochemistry 49, 972–85

Garza AM et al. (2010) Mol Cell Biol 30, 220–30

Kobayashi Y et al. (2012) Pulm Pharmacol Ther 25, 201–7

Bouazza B et al. (2013) Am J Respir Cell Mol Biol ,

Johnstone CN et al. (2008) Mol Cell Biol 28, 687–704

Lange CA et al. (2000) Proc Natl Acad Sci U S A 97, 1032–7

Shen T et al. (2001) Mol Cell Biol 21, 6122–31

Narayanan R et al. (2005) Mol Cell Biol 25, 2885–98

Daniel AR et al. (2007) Mol Endocrinol 21, 2890–906

Daniel AR and Lange CA (2009) Proc Natl Acad Sci U S A 106, 14287–92

Busia L et al. (2011) Mol Cell Endocrinol 333, 37–46

Hagan CR et al. (2011) Mol Cell Biol 31, 2439–52

Hagan CR et al. (2013) Nucleic Acids Res 41, 8926–42

Bruck N et al. (2009) EMBO J 28, 34–47

Hoshikawa Y et al. (2011) Cancer Sci 102, 934–41

Zimmerman TL et al. (2006) J Biol Chem 281, 15434–40

Zhang Z et al. (2010) J Cell Physiol 224, 433–42


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 5,675,063.

8595
Nuclear Receptor Antibody Sampler Kit